12,372 trials
Uremic Pruritus
Primary: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily…
Colorectal Cancer
Primary: Overall Survival (OS) — 14.29; 13.83; 13.17; 12.12 months — p=0.3629
Hypertriglyceridemia
Primary: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect — -5.6; -17.5; 5.9 Percent change from baseline — p=<0.0001
Hypertriglyceridemia
Primary: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect — -7.0; -26.6; 9.7 Percent change from baseline — p=<0.0001
Systemic Lupus Erythematosus
Primary: Percentage of Participants With a State of Disease Control at Week 52 — 16.7; 19.4; 25.5 Percentage of participants — p=0.5342
Cerebral Adrenoleukodystrophy (CALD)
Primary: Percentage of Participants Who Were Alive and Have None of the 6 Major Functional Disabilities (MFDs) at Month 24 and Without Allo-HSCT or Rescue Cell Administration…
Acromegaly
Primary: Proportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase — 50; 37 Participants
Osteoarthritis
Primary: Visual Analog Scale (VAS) Pain Score — 64; 61 score on a scale
Multiple Sclerosis
Primary: Annualized Rate of Confirmed Relapses — 0.344; 0.283; 0.255 relapse per year — p=0.0746
Diabetic Macular Edema
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 — 12.2; 11.0 Scores on a scale — p=0.099
Pneumonia, Pneumococcal
Primary: Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies Four Weeks Post-Booster — 8.45; 2.90; 5.87; 1.54 μg/mL
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) < Lower Limit of Quantification (LLOQ) 12 Weeks After Discontinuation of Treatment (SVR12) — 100.0…
Post Partum Hemorrhage
Primary: Number of Participants With Postpartum Haemorrhage (PPH) — 48; 54; 56; 71 Participants — p=0.549
Heavy Menstrual Bleeding · Uterine Fibroid
Primary: Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA — 71.2…
Epithelial Ovarian Cancer
Primary: Efficacy: Progression-free Survival (PFS) — 4.3; 2.8; 5.3; 2.8 Months — p=0.0220